First Affiliated Hospital of Fujian Medical University
fjfyy.comTotal trials
85
Active
44
Phase 3
1
Total enrollment
49,998
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 36 of 36 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| 68Ga-PSMA-11 | — | — | — | 3 | |||
| 225Ac-LNC1011 | — | — | — | — | — | 2 | |
| Envafolimab | — | — | — | — | — | 1 | |
| Fruquintinib | — | — | — | — | — | 1 | |
| 68Ga-P16-093 | — | — | — | — | — | 1 | |
| 68Ga-G21 | — | — | — | — | — | 1 | |
| 68Ga-G23 | — | — | — | — | — | 1 | |
| 68Ga-PSMA-CYC | — | — | — | — | — | 1 | |
| CYC | — | — | — | — | — | 1 | |
| 177Lu-P17-088 | — | — | — | — | — | 1 | |
| 68Ga-MGS5 | — | — | — | — | — | 1 | |
| Adebrelimab | — | — | — | — | — | 1 | |
| Apatinib | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| 68Ga-FAPI/18F-FDG | — | — | — | — | — | 3 | |
| 68Ga-JH04 | — | — | — | — | — | 2 | |
| 18F-FAPIBiotin | — | — | — | — | — | 1 | |
| 68Ga-NI-FAPI | — | — | — | — | — | 1 | |
| 68Ga-AAZTA-093 | — | — | — | — | — | 1 | |
| 68Ga-PSMA-11//68Ga-PSMA-617 | — | — | — | — | — | 1 | |
| 68Ga-JH12 | — | — | — | — | — | 1 | |
| 3.70 GBq (100 mCi) of 177Lu-JH04 | — | — | — | — | — | 1 | |
| 5.55 GBq (150 mCi) of 177Lu-JH04 | — | — | — | — | — | 1 | |
| 7.40 GBq (200 mCi) of 177Lu-JH04 | — | — | — | — | — | 1 | |
| 68Ga-dPNE | — | — | — | — | — | 1 | |
| 18F-FDG | — | — | — | — | — | 1 | |
| 68Ga-FAPI-Biotin | — | — | — | — | — | 1 | |
| 68Ga-AAZTA-NI-093 | — | — | — | — | — | 1 | |
| 68Ga-DOTA-NI-FAPI04 | — | — | — | — | — | 1 | |
| Rifampicin | — | — | — | — | — | 1 | |
| PegIFNα2b+Nucleoside analog | — | — | — | — | — | 1 | |
| PegIFNα2b+Nucleoside analog+Bacteroides fragilis+Branched-Chain Amino Acids | — | — | — | — | — | 1 | |
| Antibiotics treatment | — | — | — | — | — | 1 | |
| Triplet-primed PCR or Long-read sequencing | — | — | — | — | — | 1 | |
| LIA with different doses of Diprospan | — | — | — | — | — | 1 |
Next readouts
- 2023-12-31
- 2024-07-01
- 2024-12
- 2025-04-01
- 2025-05-01
- 2025-06-30
- 2025-07-31
- 2025-08-31
- 2025-08-31
- 2025-10-01
Top conditions
- Tumor7
- Positron-Emission Tomography7
- Prostate Cancer5
- Malignant Neoplasm4
- Prostate Cancer (Adenocarcinoma)4
- Total Knee Arthroplasty3
- Spontaneous Intracerebral Hemorrhage2
- Periprosthetic Joint Infection2
Frequently asked questions about First Affiliated Hospital of Fujian Medical University
- How many clinical trials does First Affiliated Hospital of Fujian Medical University have on ClinicalTrials.gov?
- First Affiliated Hospital of Fujian Medical University is listed as the lead sponsor on 85 clinical trials in ClinicalTrials.gov, 44 of which are currently active (recruiting, enrolling, or ongoing).
- How many of First Affiliated Hospital of Fujian Medical University's trials are in Phase 3?
- 1 of First Affiliated Hospital of Fujian Medical University's trials are in Phase 3, spread across 36 active drug programs.
- What therapeutic areas does First Affiliated Hospital of Fujian Medical University focus on?
- First Affiliated Hospital of Fujian Medical University's most-studied conditions on ClinicalTrials.gov are Tumor, Positron-Emission Tomography, Prostate Cancer, Malignant Neoplasm, Prostate Cancer (Adenocarcinoma).
- When are First Affiliated Hospital of Fujian Medical University's next clinical trial readouts?
- First Affiliated Hospital of Fujian Medical University has 10 upcoming primary-completion readouts tracked here; the soonest is “Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI.”, expected around 2023-12-31.